Company registration number 11344817 (England and Wales)
ADVANCED CLINICAL RESEARCH SERVICES LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
ADVANCED CLINICAL RESEARCH SERVICES LIMITED
COMPANY INFORMATION
Director
G Belgrave
Company number
11344817
Registered office
Building 2
Guildford Business Park
Guildford
Surrey
GU2 8XG
Auditor
Grant Thornton
13 - 18 City Quay
Dublin 2
ADVANCED CLINICAL RESEARCH SERVICES LIMITED
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 6
ADVANCED CLINICAL RESEARCH SERVICES LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
4
18,650
41,403
Current assets
Debtors
5
1,323,526
1,148,458
Cash at bank and in hand
134,697
268,969
1,458,223
1,417,427
Creditors: amounts falling due within one year
6
(526,986)
(745,119)
Net current assets
931,237
672,308
Total assets less current liabilities
949,887
713,711
Provisions for liabilities
Deferred tax liability
4,662
10,351
(4,662)
(10,351)
Net assets
945,225
703,360
Capital and reserves
Called up share capital
1
1
Profit and loss reserves
945,224
703,359
Total equity
945,225
703,360

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 23 June 2025
G Belgrave
Director
Company registration number 11344817 (England and Wales)
ADVANCED CLINICAL RESEARCH SERVICES LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 January 2023
1
478,520
478,521
Year ended 31 December 2023:
Profit and total comprehensive income
-
224,839
224,839
Balance at 31 December 2023
1
703,359
703,360
Year ended 31 December 2024:
Profit and total comprehensive income
-
241,865
241,865
Balance at 31 December 2024
1
945,224
945,225
ADVANCED CLINICAL RESEARCH SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
1
Accounting policies
Company information

Advanced Clinical Research Services Limited is a private company limited by shares incorporated in England and Wales. The registered office is Building 2, Guildford Business Park, Guildford, Surrey, GU2 8XG.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Revenue comprises sales of services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

 

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
50% Straight line
Computers
33% Straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

ADVANCED CLINICAL RESEARCH SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -
1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6
Financial instruments
Basic financial liabilities

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

ADVANCED CLINICAL RESEARCH SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 5 -
3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
58
48
4
Tangible fixed assets
Fixtures and fittings
Computers
Total
£
£
£
Cost
At 1 January 2024
263
86,764
87,027
Additions
-
0
733
733
At 31 December 2024
263
87,497
87,760
Depreciation and impairment
At 1 January 2024
263
45,361
45,624
Depreciation charged in the year
-
0
23,486
23,486
At 31 December 2024
263
68,847
69,110
Carrying amount
At 31 December 2024
-
0
18,650
18,650
At 31 December 2023
-
0
41,403
41,403
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
1,303,659
1,126,747
Other debtors
3,944
5,465
Prepayments and accrued income
15,923
16,246
1,323,526
1,148,458
ADVANCED CLINICAL RESEARCH SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 6 -
6
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
22,155
1,751
Amounts owed to group undertakings
78,190
32,341
Corporation tax
158,360
69,540
Other taxation and social security
176,838
159,511
Other creditors
-
0
13,069
Accruals and deferred income
91,443
468,907
526,986
745,119
7
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

Senior Statutory Auditor:
Tracey Sullivan
Statutory Auditor:
Grant Thornton
Date of audit report:
23 June 2025
8
Ultimate controlling party

The company's immediate parent is Advanced Clinical GmbH, incorporated in Germany.

 

The principle place of business and registered address of the parent company Advanced Clinical GmbH is:

Thurn-und-Taxis-Platz 6

D-60313 Frankfurt

Germany

The ultimate controlling party is Advanced Clinical LLC / United States of America.

 

The principle place of business and registered address of Advanced Clinical LLC / United States of America is:

6 Parkway North

Suite 100

Deerfield, IL 60015

2024-12-312024-01-01falsefalsefalse23 June 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityG Belgrave113448172024-01-012024-12-3111344817bus:Director12024-01-012024-12-3111344817bus:RegisteredOffice2024-01-012024-12-31113448172024-12-31113448172023-12-3111344817core:FurnitureFittings2024-12-3111344817core:ComputerEquipment2024-12-3111344817core:FurnitureFittings2023-12-3111344817core:ComputerEquipment2023-12-3111344817core:ShareCapital2024-12-3111344817core:ShareCapital2023-12-3111344817core:RetainedEarningsAccumulatedLosses2024-12-3111344817core:RetainedEarningsAccumulatedLosses2023-12-3111344817core:ShareCapital2022-12-3111344817core:RetainedEarningsAccumulatedLosses2022-12-3111344817core:RetainedEarningsAccumulatedLosses2023-01-012023-12-31113448172023-01-012023-12-3111344817core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3111344817core:FurnitureFittings2024-01-012024-12-3111344817core:ComputerEquipment2024-01-012024-12-3111344817core:FurnitureFittings2023-12-3111344817core:ComputerEquipment2023-12-31113448172023-12-3111344817core:CurrentFinancialInstruments2024-12-3111344817core:CurrentFinancialInstruments2023-12-3111344817bus:PrivateLimitedCompanyLtd2024-01-012024-12-3111344817bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3111344817bus:FRS1022024-01-012024-12-3111344817bus:Audited2024-01-012024-12-3111344817bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP